Drawing for CSL

USPTO serial 87683942

CSL

Reviewed by CopyMark Law Group

Reg. 5578603Status 704Registered
Filing date
Status date
Registration date
Oct 9, 2018
Examiner
KLEINMAN, CORINNE ANNE
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 704 applies to Madrid Protocol extensions of protection in the U.S. Section 71 (similar to Section 8) showing continued use was accepted. The U.S. extension remains active. Follow Madrid and USPTO deadlines for the next renewal cycle.

Status 704: Status 704 applies to Madrid Protocol extensions of protection in the U.S. Section 71 (similar to Section 8) showing continued use was accepted. The U.S. extension remains active.

Need help with CSL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Scott D. Woldow

Scott D. Woldow Smith, Gambrell & Russell, LLP1055 Thomas Jefferson Street, NWSuite 400Washington, DC 20007

Goods and services

ClassDescriptionStatusFirst use
016[ Printed matter and publications, namely, printed instructional material and magazines featuring pharmaceutical products, vaccines, blood, blood products, bleeding disorders, blood fractionations, rhesus prophylaxis and human autoimmune disorders; ] printed instructional and teaching materials in the field of [ pharmaceutical products, vaccines, ] blood, blood products, [ bleeding disorders, ] blood fractionations [ , rhesus prophylaxis and human autoimmune disorders ] ; [ brochures, ] pamphlets [ and informational flyers ] in the field of pharmaceutical products [ , vaccines, blood, blood products, bleeding disorders, blood fractionations, rhesus prophylaxis and human autoimmune disorders ] ; posters [ and stationery ] relating to pharmaceutical products, [ vaccines, ] blood, blood products, [ bleeding disorders, ] blood fractionations [ , rhesus prophylaxis and human autoimmune disorders ]ACTIVE—
040[ Treatment of biological products, namely, custom manufacturing and fractionation of blood ]SECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 7, 2025NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Jul 7, 20258.PRREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED—
Jul 7, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 28, 2025ES8RTEAS SECTION 8 RECEIVED—
Oct 9, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Oct 11, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 11, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 11, 2022ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Oct 11, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 11, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 11, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Dec 17, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 17, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 9, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 24, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 24, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 4, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 21, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 31, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 31, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 31, 2018ALIEASSIGNED TO LIE—
May 24, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 24, 2018ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Apr 23, 2018GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Apr 23, 2018GNSLLETTER OF SUSPENSION E-MAILED—
Apr 23, 2018CNSLSUSPENSION LETTER WRITTEN—
Mar 29, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Mar 29, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 29, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 29, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 12, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 12, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 12, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 27, 2018DOCKASSIGNED TO EXAMINER—
Nov 27, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 17, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance